Sorafenib

Catalog No.S7397 Synonyms: BAY 43-9006

Sorafenib Chemical Structure

Molecular Weight(MW): 464.82

Sorafenib is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM in cell-free assays, respectively.

Size Price Stock Quantity  
USD 147 In stock
USD 270 In stock
USD 670 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 60 Publications

7 Customer Reviews

  • Inhibition of the MAPK signaling pathway results in downregulation of Plk-1 protein expression. (a) WB analysis for Plk-1 protein after treatment of human melanoma cell lines M14 and WM-115 with MEK 1/2 inhibitor PD98059 (10 μM), JNK inhibitor (16 μM), p38 inhibitor SB203580 (20 μM), and multikinase inhibitor sorafenib (10 μM) for 48 h showing significant reduction in the expression of Plk-1 protein after 48 hours. (b) Annexin V/PI staining of cells treated with MAPK inhibitors and induction of apoptosis. JNK, c-Jun N-terminal kinase; MAPK, mitogen-activated protein kinase; MEK 1/2, mitogen-activated protein kinase kinase 1/2; Plk-1, polo-like kinase 1; WB, western blot.

    J Invest Dermatol 2011 131, 1886–1895. Sorafenib purchased from Selleck.

    (A) were exposed to 200 uM gentamicin for various time periods. Immunoreactivity for phosphorylated JNK (green) and c-Jun (blue) in hair cells increased in a time-dependent manner. B. Hair cells from explants pre-treated with 500 nM sorafenib displayed a near complete inhibition of JNK activation at all time points analyzed.

    J Neurosci 2013 33(7), 3079-93. Sorafenib purchased from Selleck.

  • Sorafenib in combination with metformin or the AMPK activator salicylate enhances AMPK activation. a, b, AMPK activation with the combination of sorafenib and metformin in LKB1 mutant KRAS mutant (A549 and H460) NSCLC cells (a), LKB1 wild-type KRAS mutant (H358) (b, left panel) or LKB1 mutant KRAS wild-type (H838) NSCLC cells (b, right panel). Cells were treated for 48 hr with sorafenib (1-3 uM), metformin (1–1.5 mM) or the combination of sorafenib and metformin with the same concentrations as were used for the individual treatments. c, AMPK activation with the combination of sorafenib and salicylate in LKB1 mutant KRAS mutant (A549 and H460) or LKB1 mutant KRAS wild-type (H838) NSCLC cells. Cells were treated for 48 hr with sorafenib (1–3 uM), salicylate (1–1.5 mM) or the combination of sorafenib and salicylate with the same concentrations as were used for the individual treatments. Cell lysates were harvested for western blot analysis and probed with the indicated antibodies.

    Int J Cancer 2012 10.1002/ijc.29113.. Sorafenib purchased from Selleck.

    Involvement of EV linc-VLDLR in tumor cell responses to chemotherapy. Cells were incubated with sorafenib, camptothecin, or doxorubicin. EVs were obtained after 24 hours, and qRT-PCR was performed for linc-VLDLR. The bars represent the mean ?SEM of the increase in cell viability from 3 independent studies. *, P < 0.05.

    Mol Cancer Res 2014 12(10), 1377-87. Sorafenib purchased from Selleck.

  • Sorafenib and PX-866 interact to suppress tumor growth in vivo. Mice were PO administered vehicle diluent, sorafenib (25 mg/kg), PX-866 (2 mg/kg), or the drug combination QD for 3 days. Animals were monitored daily and tumor volume determined every fifth day. Tumors from animals were isolated at day 15 and fixed, sectioned (10-um), and stained against proliferation (Ki67 staining), phospho-ERK1/2 and phospho-AKT staining, the levels of tumor cell apoptosis/cleaved caspase 3, as well as with H&E and 4′,6-diamidino-2-phenylindole (DAPI).

    Mol Pharmacol 2013 84(4), 562-71. Sorafenib purchased from Selleck.

    Effects of sorafenib or sunitinib on LicA-induced cell death, ER stress responses, PLCc1, Ca2+, and ROS in HepG2 cells. HepG2 cells were pretreated with sorafenib or sunitinib for 1 h, then treated with LicA or TG for 1 h (for P-eIF2a and P-PLCc1) or 24 h (for CHOP, ATF6a(p90), and caspase-4). The cell lysates were subjected to Western blot analyses using antibodies against CHOP, ATF6a(p90), caspase-4(C), P-eIF2a, and b-actin.

    Apoptosis 2014 19(4), 682-97. Sorafenib purchased from Selleck.

  • PLoS One 2013 8(1), e54595. Sorafenib purchased from Selleck.

Purity & Quality Control

Choose Selective Raf Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Sorafenib is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM in cell-free assays, respectively.
Targets
Raf-1 [1]
(Cell-free assay)
mVEGFR2(Flk1) [1]
(Cell-free assay)
mVEGFR3 [1]
(Cell-free assay)
B-Raf [1]
(Cell-free assay)
B-Raf (V599E) [1]
(Cell-free assay)
6 nM 15 nM 20 nM 22 nM 38 nM
In vitro

Sorafenib inhibits both wild-type and V599E mutant B-Raf activity with IC50 of 22 nM and 38 nM, respectively. Sorafenib also potently inhibits mVEGFR2 (Flk-1), mVEGFR3, mPDGFRβ, Flt3, and c-Kit with IC50 of 15 nM, 20 nM, 57 nM, 58 nM, and 68 nM, respectively. Sorafenib weakly inhibits FGFR-1 with IC50 of 580 nM. Sorafenib tosylate is not active against ERK-1, MEK-1, EGFR, HER-2, IGFR-1, c-Met, PKB, PKA, cdk1/cyclinB, PKCα, PKCγ, and pim-1. Sorafenib markedly inhibits VEGFR2 phosphorylation in NIH 3T3 cells with IC50 of 30 nM, and Flt-3 phosphorylation in HEK-293 cells with IC50 of 20 nM. Sorafenib potently blocks MEK 1/2 and ERK 1/2 phosphorylation in most cell lines but not in A549 or H460 cells, while having no effect on inhibition of the PKB pathway. Sorafenib inhibits the proliferation of HAoSMC and MDA-MB-231 cells with IC50 of 0.28 μM and 2.6 μM, respectively. [1] In addition to inhibition of the RAF/MEK/ERK signaling pathway, Sorafenib significantly inhibits the phosphorylation of eIF4E and down-regulates Mcl-1 levels in hepatocellular carcinoma (HCC) cells in a MEK/ERK-independent manner. Sorafenib inhibits the proliferation of PLC/PRF/5 and HepG2 cells with IC50 of 6.3 μM and 4.5 μM, respectively, and leads to the significant induction of apoptosis. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rpVmlEPTB;MD6wNFAxODNyMzFOwG0> MUfTRW5ITVJ?
MONO-MAC-6 MlH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHrR3JKSzVyPUCuNFA1OThizszN MWDTRW5ITVJ?
ALL-PO MlHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\FWWlEPTB;MD6wN|E5PCEQvF2= MXHTRW5ITVJ?
NKM-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DTTWlEPTB;MD6wO|QyPiEQvF2= NXvibHloW0GQR1XS
CGTH-W-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1L4Z2lEPTB;MD6yOVAzOiEQvF2= MX;TRW5ITVJ?
BB65-RCC NX2zdFk2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7hTWM2OD1yLkS3NFc{KM7:TR?= Mmr3V2FPT0WU
NOS-1 NV70fJNNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnNeYgxUUN3ME2wMlU3OzZizszN MofkV2FPT0WU
SH-4 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\ye5ZvUUN3ME2wMlY2PjF|IN88US=> NHLpPWRUSU6JRWK=
HOP-62 NVfJVYNVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TzW2lEPTB;MD64OVA5QCEQvF2= M{\Ib3NCVkeHUh?=
HCC2998 NVL0TYQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2W3T2lEPTB;MD64PFgyQCEQvF2= M37ad3NCVkeHUh?=
GDM-1 Mo\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfTTWM2OD1yLkmwOlk5KM7:TR?= M{PPcHNCVkeHUh?=
KM12 MlvMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\5OmlEPTB;MT6wNlA6QCEQvF2= M3HGfXNCVkeHUh?=
LB2518-MEL NV7G[5E5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTFwMkC4NFkh|ryP NIP3UYFUSU6JRWK=
NCI-H1436 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTFwMkG2O|gh|ryP NUfi[XROW0GQR1XS
EM-2 MmjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4joOGlEPTB;MT6zOVU4QCEQvF2= MXHTRW5ITVJ?
LAMA-84 NHnOb4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHQUpltUUN3ME2xMlM4PjR6IN88US=> M1\uOHNCVkeHUh?=
KG-1 MlPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnpW3VKSzVyPUGuOFc6OzVizszN MWHTRW5ITVJ?
A388 Mki0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfYTWM2OD1zLkW5NVY2KM7:TR?= NHfhbJlUSU6JRWK=
no-10 NIPJOGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrDeIhKSzVyPUGuOlE4OjZizszN NYWwfYhvW0GQR1XS
SF126 NY\TeHdHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfuZpdKSzVyPUGuOlM5OTJizszN NIGwU3FUSU6JRWK=
MEG-01 MoXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1frbWlEPTB;MT64NFk5KM7:TR?= M2fCd3NCVkeHUh?=
A3-KAW MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWq1OHlXUUN3ME2xMlg5PDJizszN NInpbFdUSU6JRWK=
D-247MG MmrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\4TWM2OD1{LkG0OFgh|ryP MlizV2FPT0WU
OVCAR-4 M3v1UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLzbI5KSzVyPUKuNlE{QTNizszN MonQV2FPT0WU
NCI-SNU-1 NFLre3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\hTWM2OD1{LkOxOlIh|ryP NEjjUJhUSU6JRWK=
NCI-H2171 NIHnS|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmezTWM2OD1{LkO5O|Y1KM7:TR?= NHTEXYhUSU6JRWK=
SIG-M5 M3jqRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\MNot[UUN3ME2yMlQzOjR{IN88US=> NGHCeI9USU6JRWK=
BE-13 NIXsU2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTJwNkm2NFkh|ryP M{D6O3NCVkeHUh?=
K052 NWTSW2s5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\lcWJKSzVyPUKuO|Q3OTZizszN NHjZSJVUSU6JRWK=
L-540 M2PMOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPwNoZKSzVyPUKuO|U4QDlizszN MVXTRW5ITVJ?
KMOE-2 MkjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTJwOEGzOUDPxE1? MWTTRW5ITVJ?
MFH-ino NHrvV|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXHVotnUUN3ME2yMlkzOTh3IN88US=> NV61d21uW0GQR1XS
HL-60 NYfncldOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLTTWM2OD1|LkC2Nlk6KM7:TR?= MWTTRW5ITVJ?
HCC2218 NInUXnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTNwMUKwNFMh|ryP NX\YVZRlW0GQR1XS
TE-5 NHXtVoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzjd5ZKSzVyPUOuNVMyPjJizszN MofzV2FPT0WU
MZ1-PC M2fTWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTmWIZKSzVyPUOuOFc2ODlizszN NEXodGFUSU6JRWK=
MRK-nu-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTNwNkG0Olgh|ryP NUL1Z21EW0GQR1XS
MZ7-mel M{i1SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLkR2xRUUN3ME2zMlY3ODl7IN88US=> MV3TRW5ITVJ?
BC-1 NGLJ[4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nPPGlEPTB;Mz63OFAzKM7:TR?= NXfsV|NCW0GQR1XS
ST486 NWO4[Zk5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfkOWM5UUN3ME2zMlg{Pjd|IN88US=> MX;TRW5ITVJ?
KS-1 MljxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTwTWM2OD1|Lki4NVk5KM7:TR?= MVzTRW5ITVJ?
SK-NEP-1 NX3S[llZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\DUJY5UUN3ME20MlE3QDF3IN88US=> MWfTRW5ITVJ?
BC-3 NX7WbXBRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\jTWM2OD12LkKzN|kyKM7:TR?= NV\tRYY6W0GQR1XS
NCI-H1581 NHmyZXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLmV4R1UUN3ME20MlI5Pzl6IN88US=> MXnTRW5ITVJ?
MHH-PREB-1 NFTjfpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzoR4l5UUN3ME20MlQxPDh2IN88US=> MnPtV2FPT0WU
NOMO-1 NInBOoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnyVGxKSzVyPUSuOFg6ODVizszN NVXvblJFW0GQR1XS
QIMR-WIL NVfZdoY5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIS2bIZKSzVyPUWuNFczQTRizszN Ml;UV2FPT0WU
SF539 M2LpfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTVwMUOyNlch|ryP NUDFfpNLW0GQR1XS
TE-12 NED4fZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELNNoVKSzVyPUWuNlQ6OjlizszN MmDKV2FPT0WU
NCI-H510A MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPzTWM2OD13LkSxOlg2KM7:TR?= M{GxOHNCVkeHUh?=
JAR MoLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTVwNUC4NlQh|ryP NIrHbHFUSU6JRWK=
no-11 MoP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTnTWM2OD13LkezOVY5KM7:TR?= MmG0V2FPT0WU
BV-173 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTVwOUW2PFIh|ryP MmrSV2FPT0WU
SR NXfhW5FNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M331cWlEPTB;Nj6wNFY4QCEQvF2= MoLKV2FPT0WU
MOLT-16 NUT0WFVWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7LTWM2OD14LkK1NlY3KM7:TR?= MWLTRW5ITVJ?
MZ2-MEL NUGxSFVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYmyfpVOUUN3ME22MlMyQDN7IN88US=> NYXkc|BOW0GQR1XS
SW954 NHvXWWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHQTWM2OD14LkS1PFY3KM7:TR?= M3fO[HNCVkeHUh?=
ML-2 NV7GdWNtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTZwNUK4OFkh|ryP MVLTRW5ITVJ?
OCI-AML2 MoD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTZwNkGwOlIh|ryP NVG2NWFEW0GQR1XS
SIMA NXjoUItDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTdwMECxNFEh|ryP M{HLR3NCVkeHUh?=
DOHH-2 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTdwMEW2O|Yh|ryP M2izbnNCVkeHUh?=
697 Mmq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrx[mVOUUN3ME23MlA2QTh7IN88US=> NYL0SVRiW0GQR1XS
NB1 M3K0UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPOdXpRUUN3ME23MlQxPDB5IN88US=> NYHMVG9[W0GQR1XS
D-392MG M4LCTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTdwNkK2OlMh|ryP MXXTRW5ITVJ?
ES8 M4LlRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzmO|ZKSzVyPUeuO|Y2ODNizszN MUXTRW5ITVJ?
RPMI-8226 NG\VW2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonqTWM2OD15Lki0OVEyKM7:TR?= M4ruVnNCVkeHUh?=
IST-MEL1 M{nCbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nLN2lEPTB;OD60NFAxOiEQvF2= MoLaV2FPT0WU
NB14 NIrE[5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTBdJpKSzVyPUiuOlMyOzNizszN NEOyeG9USU6JRWK=
HD-MY-Z MmjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDhSoZKSzVyPUiuOlM4PDZizszN NVT5Z2NXW0GQR1XS
TE-10 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU[2NHQ5UUN3ME24Mlc3OzV|IN88US=> NXvUTIt{W0GQR1XS
LC-1F MlzYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HWO2lEPTB;OT6xNFg{PCEQvF2= NVfWSFNvW0GQR1XS
OS-RC-2 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDiTWM2OD17LkGxNlQ{KM7:TR?= NVXud2NVW0GQR1XS
NCI-SNU-16 NHrmVZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfBTWM2OD17LkKxNFI3KM7:TR?= NXPoNnByW0GQR1XS
SHP-77 NWLUZVJRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHrZo5KSzVyPUmuO|E3PjJizszN Ml25V2FPT0WU
A4-Fuk MkD1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnwTJFKSzVyPUmuO|U3OSEQvF2= MoLpV2FPT0WU
NB6 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXSVmdKSzVyPUmuO|YxOjlizszN NHq2W|RUSU6JRWK=
JiyoyeP-2003 NUnvU2tIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGS2NmZKSzVyPUGwMlQ4PDVizszN NG\CZ|hUSU6JRWK=
DMS-114 NFqyU|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF[4[oJKSzVyPUGwMlU1PDFizszN NIjXbVhUSU6JRWK=
NB7 MoKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTFyLke1NlYh|ryP MWrTRW5ITVJ?
NCI-H747 M4fUfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXRTWM2OD1zMT6xNlE3KM7:TR?= MVrTRW5ITVJ?
HH MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXufZNKSzVyPUGxMlM5PzZizszN NYTCTnh[W0GQR1XS
EW-18 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjITWM2OD1zMT65NFQ1KM7:TR?= M{HkWnNCVkeHUh?=
CHP-126 Mkj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEX1NpZKSzVyPUGxMlk4OzhizszN MVPTRW5ITVJ?
NTERA-S-cl-D1 Ml7nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;qTWM2OD1zMj6wNlc5KM7:TR?= NG\QfVdUSU6JRWK=
DEL NIfBXZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTF{LkC5PFUh|ryP MmXiV2FPT0WU
LU-139 Mor0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH[4N3NKSzVyPUGyMlU1OTNizszN MXXTRW5ITVJ?
P30-OHK MmXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLFTZJEUUN3ME2xNk42PDd7IN88US=> NGPZWFdUSU6JRWK=
NCI-H1522 NHLQVmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\aTWM2OD1zMj63OFYh|ryP M2TLTXNCVkeHUh?=
NCI-H1299 NIPoVWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vnPWlEPTB;MUOuNlkyOSEQvF2= MmPYV2FPT0WU
UACC-257 NEjERWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfWfmZJUUN3ME2xN{42OTJ4IN88US=> NG\pPGNUSU6JRWK=
Calu-6 NGDoU|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTF|Lk[wOFYh|ryP MY\TRW5ITVJ?
NCI-H1882 MoDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\UTWM2OD1zMz64OVU2KM7:TR?= MorUV2FPT0WU
BB30-HNC MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoH3TWM2OD1zND6wOlA6KM7:TR?= MXvTRW5ITVJ?
ES1 MlzQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLGWIpKSzVyPUG0MlE2PTFizszN NV3ISZVyW0GQR1XS
NCI-H1694 NH[1[olIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXDfnVKSzVyPUG0MlQ5OTFizszN M4q2ZXNCVkeHUh?=
IST-SL1 M{HRUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFL2dpBKSzVyPUG0Mlk3OTZizszN NUTTXYkzW0GQR1XS
ECC4 NVrBOVZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvWdmxxUUN3ME2xOU4xPTV6IN88US=> NV7YN5ZNW0GQR1XS
MDA-MB-134-VI M3XKWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\GTWM2OD1zNT60NVMyKM7:TR?= MUjTRW5ITVJ?
SCH MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moj4TWM2OD1zNT60O|I5KM7:TR?= NUTxOWhwW0GQR1XS
SK-N-FI NFjwZWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHz2S41KSzVyPUG1MlY2OzRizszN M3LTTHNCVkeHUh?=
HDLM-2 NWLzbIxRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfiXYI1UUN3ME2xOk4xPzF2IN88US=> MXnTRW5ITVJ?
Ramos-2G6-4C10 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTF4LkGyPVch|ryP MX3TRW5ITVJ?
EW-24 M4rsOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{G5XWlEPTB;MU[uNVY3OSEQvF2= MWjTRW5ITVJ?
NCI-H2141 M{HCUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTF4LkG4PUDPxE1? Mn[4V2FPT0WU
LC4-1 Ml3TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fFUWlEPTB;MU[uOlEyQSEQvF2= NVXMSIc{W0GQR1XS
HT-144 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LvemlEPTB;MUeuNFA3KM7:TR?= NUf6O5Z2W0GQR1XS
SK-MEL-1 NVqz[|BWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTF5LkCwO|Ih|ryP M{nQdnNCVkeHUh?=
SCC-15 M37rXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjweY5oUUN3ME2xO{4yPjN6IN88US=> NInLToRUSU6JRWK=
C8166 NVHP[ZdYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTF5Lk[4N|Mh|ryP Mm\SV2FPT0WU
GOTO M4XZ[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2SyOmlEPTB;MUeuPFM1PCEQvF2= NXrWNnhLW0GQR1XS
COR-L279 NIjFXmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TnNWlEPTB;MUiuNVM3OiEQvF2= NH;ZdoNUSU6JRWK=
K-562 Mki4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrKRlNKSzVyPUG4MlcyPDNizszN NVjhU3d6W0GQR1XS
ES3 M4nVdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTF6LkiwOFEh|ryP NGnpXW9USU6JRWK=
LU-165 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HxNGlEPTB;MUmuO|AxQCEQvF2= NHXYemJUSU6JRWK=
KM-H2 MofUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTJyLkOxPFQh|ryP MoP1V2FPT0WU
RL NUTOcmx6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTJyLkm2PVIh|ryP M1TCb3NCVkeHUh?=
EW-3 M2TncWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHofIh1UUN3ME2yNU4yQDh7IN88US=> NFrmbYxUSU6JRWK=
A101D Mki5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPNTWM2OD1{MT6zO|UzKM7:TR?= MWPTRW5ITVJ?
HUTU-80 NX7BPJRxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnH1TWM2OD1{MT6zPVQ3KM7:TR?= NX7pSoZjW0GQR1XS
NCI-H23 M1Hqb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVviR4FOUUN3ME2yNU4{QTl{IN88US=> M2\l[nNCVkeHUh?=
PF-382 M1Xodmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHJ[XA{UUN3ME2yNU41PDB|IN88US=> Mn3PV2FPT0WU
LB373-MEL-D NUDncmMxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TyU2lEPTB;MkGuOVYyPSEQvF2= MXfTRW5ITVJ?
TE-8 MnLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;aRXhEUUN3ME2yNU43Ozl2IN88US=> M3vRe3NCVkeHUh?=
TE-9 NVu4UGd6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjoTWM2OD1{MT64OVE{KM7:TR?= Mn76V2FPT0WU
Daudi NWjpTohpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LGbmlEPTB;MkGuPVMxPCEQvF2= M3eyVnNCVkeHUh?=
D-542MG M1nkdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rvSGlEPTB;MkKuNFI2PiEQvF2= M4fLdHNCVkeHUh?=
U-698-M MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrHbVhKSzVyPUKyMlQ3ODNizszN NIHaVnVUSU6JRWK=
ES6 M1W2eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfiTWM2OD1{Mj63N|Y3KM7:TR?= M4CzdHNCVkeHUh?=
DU-4475 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlr4TWM2OD1{Mz64PFk4KM7:TR?= NFO0ZYxUSU6JRWK=
ECC12 M4rUUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPWNJlOUUN3ME2yOE4zQDB|IN88US=> Ml6wV2FPT0WU
C2BBe1 NHi1UZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfv[2RKSzVyPUK0MlMzOzlizszN MoX2V2FPT0WU
IST-SL2 NYDsXXlsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrHdIlKSzVyPUK0MlQ{PjJizszN MmfaV2FPT0WU
DJM-1 NU\abHNCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfFW4hFUUN3ME2yOE42OjJzIN88US=> M{O1Z3NCVkeHUh?=
DMS-153 M{\xSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4e3bmlEPTB;MkSuPFYyPCEQvF2= MoH0V2FPT0WU
NB13 NFvrfnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;zTWM2OD1{NT6wNlY2KM7:TR?= MYfTRW5ITVJ?
SK-N-DZ MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPzZ3NKSzVyPUK2MlM1OTRizszN MWPTRW5ITVJ?
COR-L88 M3i2Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mly0TWM2OD1{Nj61O|k3KM7:TR?= MWrTRW5ITVJ?
LU-65 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTsV|VEUUN3ME2yOk45PTN3IN88US=> MlPqV2FPT0WU
TGBC1TKB M1\te2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXj1bJgzUUN3ME2yOk46QDJ6IN88US=> NVjaT|ZiW0GQR1XS
THP-1 NUO5fVdGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn[wTWM2OD1{Nz6yNVQyKM7:TR?= MVjTRW5ITVJ?
ONS-76 M{PveGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfYTWM2OD1{Nz6zN|Ih|ryP MYfTRW5ITVJ?
LC-2-ad MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4i3OmlEPTB;MkeuOlI{OSEQvF2= NFqzfpNUSU6JRWK=
EW-13 M{DUTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTJ7LkG3OFYh|ryP NFHndFRUSU6JRWK=
MS-1 NG\KfWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTNyLkeyO|gh|ryP MVrTRW5ITVJ?
NCI-H2227 NFrjVoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTNyLkm4NFYh|ryP MoTqV2FPT0WU
LXF-289 NHTzU5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTNzLkS0PVIh|ryP NFLMWmxUSU6JRWK=
MC116 Mm\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH31PGdKSzVyPUOyMlA5OjZizszN M174ZXNCVkeHUh?=
EVSA-T Mnr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TuemlEPTB;M{KuNlU5PSEQvF2= NXXzXYFUW0GQR1XS
CTB-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTN|LkGxNFEh|ryP MlXKV2FPT0WU
COLO-320-HSR NFTmdnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTN|LkG2NFMh|ryP NE\qXJFUSU6JRWK=
NCI-H2196 NFnPN4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{f5fGlEPTB;M{OuNlU2PyEQvF2= M1zQ[3NCVkeHUh?=
LB2241-RCC NXjTfIJkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXaV2JKSzVyPUOzMlMyOzVizszN NIezTZVUSU6JRWK=
LS-513 NUO3SZR4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDVdHNKSzVyPUOzMlg3OzhizszN M32xXHNCVkeHUh?=
LP-1 NUHrUVNNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2q1fmlEPTB;M{OuPVk2PiEQvF2= MVnTRW5ITVJ?
A253 NHfrbJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2q4UWlEPTB;M{SuNlI6PiEQvF2= M3;3UnNCVkeHUh?=
SK-MM-2 NV\B[W5qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HYVWlEPTB;M{SuPVQ2OSEQvF2= NXXxbpBpW0GQR1XS
NCI-H1963 MoHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLjTWM2OD1|NT6zNFczKM7:TR?= M3H6SXNCVkeHUh?=
MMAC-SF M3zOfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTN3Lki3PFUh|ryP M{DoTXNCVkeHUh?=
LB831-BLC NYHheWx5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTN4LkC2OVQh|ryP Mlv1V2FPT0WU
WSU-NHL MoiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\LTWM2OD1|Nj6xOlQh|ryP MX7TRW5ITVJ?
CESS MnjnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjrPGZ5UUN3ME2zOk4zQDR6IN88US=> NV70OI5XW0GQR1XS
NEC8 NYL3VIlbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTN4LkW4N|Uh|ryP NYXDRmhLW0GQR1XS
KNS-42 NXrwfo5qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTN5LkGyN|ch|ryP MVXTRW5ITVJ?
MHH-CALL-2 NFruXGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HlXWlEPTB;M{euNVgzOSEQvF2= Ml\uV2FPT0WU
K5 NH3ucXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjYUFFKSzVyPUO4MlQ{KM7:TR?= MkC4V2FPT0WU
CP66-MEL NI\QfoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHyTWM2OD1|OT6wO|M{KM7:TR?= MnzkV2FPT0WU
OPM-2 MkftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFH5UGRKSzVyPUO5Mlg1OzJizszN MWnTRW5ITVJ?
IST-MES1 NFn4bVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWWz[XNyUUN3ME20NE4{ODl4IN88US=> M4XIbHNCVkeHUh?=
EC-GI-10 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTRzLkW4NFUh|ryP NIjtToVUSU6JRWK=
CTV-1 M320cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWT6O2hYUUN3ME20Nk45PDB4IN88US=> MorUV2FPT0WU
DG-75 NIntWG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTR|Lke1PVUh|ryP MmLXV2FPT0WU
KNS-81-FD NFfH[FlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoS2TWM2OD12NT60NFU5KM7:TR?= M{e2[nNCVkeHUh?=
NCI-H82 NVTPfoRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTR3LkW3OVgh|ryP NEfzXZVUSU6JRWK=
RPMI-8866 NGn1ZpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\kdpc1UUN3ME20Ok4yQDd|IN88US=> M1XxNXNCVkeHUh?=
ACN MluwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2P2emlEPTB;NE[uOFM1KM7:TR?= NFHyUldUSU6JRWK=
NCI-H1395 NYfO[3pQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvpNYNpUUN3ME20Ok41PzV4IN88US=> MXHTRW5ITVJ?
NCI-H209 NWPsU4ZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTR5LkG0NFUh|ryP Mn3RV2FPT0WU
TGW NVXs[XFrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfVZ5BKSzVyPUS5MlA4QTFizszN Mo\NV2FPT0WU
NCI-H748 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDXW4FKSzVyPUS5MlQ4PTNizszN MnrjV2FPT0WU
EKVX M1ziXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jJbmlEPTB;NEmuOlYzQCEQvF2= NGfHSI1USU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo Oral administration of Sorafenib (~60 mg/kg) demonstrates broad spectrum, dose-dependent anti-tumor activity against a variety of human tumor xenograft models including MDA-MB-231, Colo-205, HT-29, DLD-1, NCI-H460, and A549, with no evidence of toxicity. In association with the anti-tumor efficacy, Sorafenib treatment potently inhibits MEK 1/2 phosphorylation and pERK 1/2 levels in HT-29 and MDA-MB-231 xenografts but not in Colo-205 xenografts, and significantly suppresses tumor microvessel area (MVA) and microvessel density (MVD) in MDA MB-231, HT-29 and Colo-205 tumor xenografts. [1] Sorafenib treatment produces dose-dependent growth inhibition of PLC/PRF/5 tumor xenografts in SCID mice with TGIs of 49% and 78% at 10 mg/kg and 30 mg/kg, respectively, consistent with the inhibition of ERK and eIF4E phosphorylation, reduction of the microvessel area, and induction of tumor cell apoptosis. [2] Sorafenib sensitizes bax-/- cells to TRAIL in a dose-dependent manner, through a mechanism involving down-regulating NF-κB mediated Mcl-1 and cIAP2 expression. Combining Sorafenib (30-60 mg/kg) with TRAIL (5 mg/kg) show dramatic efficacy in TRAIL-resistant HCT116 bax-/- and HT29 tumor xenografts. [3]

Protocol

Kinase Assay:

[1]

+ Expand

Biochemical assays:

Recombinant baculoviruses expressing Raf-1 (residues 305–648) and B-Raf (residues 409–765) are purified as fusion proteins. Full-length human MEK-1 is generated by PCR and purified as a fusion protein from Escherichia coli lysates. Sorafenib tosylate is added to a mixture of Raf-1 (80 ng), or B-Raf (80 ng) with MEK-1 (1 μg) in assay buffer [20 mM Tris (pH 8.2), 100 mM NaCl, 5 mM MgCl2, and 0.15% β-mercaptoethanol] at a final concentration of 1% DMSO. The Raf kinase assay (final volume of 50 μL) is initiated by adding 25 μL of 10 μM γ[33P]ATP (400 Ci/mol) and incubated at 32 °C for 25 minutes. Phosphorylated MEK-1 is harvested by filtration onto a phosphocellulose mat, and 1% phosphoric acid is used to wash away unbound radioactivity. After drying by microwave heating, a β-plate counter is used to quantify filter-bound radioactivity. Human VEGFR2 (KDR) kinase domain is expressed and purified from Sf9 lysates. Time-resolved fluorescence energy transfer assays for VEGFR2 are performed in 96-well opaque plates in the time-resolved fluorescence energy transfer format. Final reaction conditions are as follows: 1 to 10 μM ATP, 25 nM poly GT-biotin, 2 nM Europium-labeled phospho (p)-Tyr antibody (PY20), 10 nM APC, 1 to 7 nM cytoplasmic kinase domain in final concentrations of 1% DMSO, 50 mM HEPES (pH 7.5), 10 mM MgCl2, 0.1 mM EDTA, 0.015% Brij-35, 0.1 mg/mL BSA, and 0.1% β-mercaptoethanol. Reaction volumes are 100 μL and are initiated by addition of enzyme. Plates are read at both 615 and 665 nM on a Perkin-Elmer VictorV Multilabel counter at ~1.5 to 2.0 hours after reaction initiation. Signal is calculated as a ratio: (665 nm/615 nM) × 10,000 for each well. For IC50 generation, Sorafenib tosylate is added before the enzyme initiation. A 50-fold stock plate is made with Sorafenib tosylate serially diluted 1:3 in a 50% DMSO/50% distilled water solution. Final Sorafenib tosylate concentrations range from 10 μM to 4.56 nM in 1% DMSO.
Cell Research:

[1]

+ Expand
  • Cell lines: MDA-MB-231, and HAoSMC
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are exposed to increasing concentrations of Sorafenib tosylate for 72 hours. Cell number is quantitated using the Cell TiterGlo ATP Luminescent assay kit. This assay measures the number of viable cells per well by measurement of luminescent signal based on amount of cellular ATP.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Female NCr-nu/nu mice implanted s.c. with MDA-MB-231, Colo-205, HT-29, H460, or A549 cells
  • Formulation: Dissolved in Cremophor EL/ethanol (50:50) as 4-fold (4 × stock solution, and diluted to 1 × with water
  • Dosages: ~60 mg/kg
  • Administration: Orally once daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 63 mg/mL (135.53 mM) warming
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 5% DMSO+45% PEG 400+ddH2O 3mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 464.82
Formula

C21H16ClF3N4O3

CAS No. 284461-73-0
Storage powder
in solvent
Synonyms BAY 43-9006

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00727233 Completed Neurofibromatosis Type I|Plexiform Neurofibroma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 8, 2008 Phase 1
NCT02989870 Not yet recruiting HepatoCellular Carcinoma|Unresectable HepatoCellular Carcinoma|Liver Cancer H. Lee Moffitt Cancer Center and Research Institute|National Comprehensive Cancer Network April 30, 2017 Phase 1
NCT01445080 Completed Leukemia|With AML and FLT3-ITD Mutations National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) August 23, 2006 Phase 1
NCT01434602 Recruiting Brain Tumor|Glioblastoma|Anaplastic Glioma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 21, 2015 Phase 1|Phase 2
NCT02988440 Not yet recruiting Hepatocellular Carcinoma Novartis Pharmaceuticals|Novartis May 2017 Phase 1
NCT03037437 Not yet recruiting Hepatocellular Cancer The University of Texas Health Science Center at San Antonio January 2017 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Raf Signaling Pathway Map

Related Raf Products

Tags: buy Sorafenib | Sorafenib supplier | purchase Sorafenib | Sorafenib cost | Sorafenib manufacturer | order Sorafenib | Sorafenib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID